CoChat

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Open access
Bilbao, Ainhoa, Spanagel, Rainer · 2022 · BMC Medicine

The DOI matches its Crossref record; 266 of the 266 references it cites were found in a registry or an index; 8 of the 17 sources its claims cite were checked for support.

Abstract

BACKGROUND: Medical cannabinoids differ in their pharmacology and may have different treatment effects. We aimed to conduct a pharmacology-based systematic review (SR) and meta-analyses of medical cannabinoids for efficacy, retention and adverse events. METHODS: We systematically reviewed (registered at PROSPERO: CRD42021229932) eight databases for randomized controlled trials (RCTs) of dronabinol, nabilone, cannabidiol and nabiximols for chronic pain, spasticity, nausea /vomiting, appetite, ALS, irritable bowel syndrome, MS, Chorea Huntington, epilepsy, dystonia, Parkinsonism, glaucoma, ADHD, anorexia nervosa, anxiety, dementia, depression, schizophrenia, PTSD, sleeping disorders, SUD and Tourette. Main outcomes and measures included patient-relevant/disease-specific outcomes, retention and adverse events. Data were calculated as standardized mean difference (SMD) and ORs with confidence intervals (CI) via random effects. Evidence quality was assessed by the Cochrane Risk of Bias and GRADE tools. RESULTS: In total, 152 RCTs (12,123 participants) were analysed according to the type of the cannabinoid, outcome and comparator used, resulting in 84 comparisons. Significant therapeutic effects of medical cannabinoids show a large variability in the grade of evidence that depends on the type of cannabinoid. CBD has a significant therapeutic effect for epilepsy (SMD - 0.5[CI - 0.62, - 0.38] high grade) and Parkinsonism (- 0.41[CI - 0.75, - 0.08] moderate grade). There is moderate evidence for dronabinol for chronic pain (- 0.31[CI - 0.46, - 0.15]), appetite (- 0.51[CI - 0.87, - 0.15]) and Tourette (- 1.01[CI - 1.58, - 0.44]) and moderate evidence for nabiximols on chronic pain (- 0.25[- 0.37, - 0.14]), spasticity (- 0.36[CI - 0.54, - 0.19]), sleep (- 0.24[CI - 0.35, - 0.14]) and SUDs (- 0.48[CI - 0.92, - 0.04]). All other significant therapeutic effects have either low, very low, or even no grade of evidence. Cannabinoids produce different adverse events, and there is low to moderate grade of evidence for this conclusion depending on the type of cannabinoid. CONCLUSIONS: Cannabinoids are effective therapeutics for several medical indications if their specific pharmacological properties are considered. We suggest that future systematic studies in the cannabinoid field should be based upon their specific pharmacology.

Overview

CoChat Summary

## TL;DR

This pharmacology-based systematic review and meta-analysis found that medical cannabinoids have condition-specific benefits, with the strongest evidence for CBD in epilepsy and Parkinsonism, dronabinol for chronic pain/appetite/Tourette, and nabiximols for chronic pain/spasticity/sleep/SUDs. Across 152 RCTs (12,123 participants), cannabinoids also produced more adverse events, while retention generally did not differ from controls.

## Key findings

  • The review included 152 RCTs with 12,123 participants, yielding 84 comparisons across 23 outcomes.
  • CBD showed significant benefit for epilepsy (SMD −0.50, 95% CI −0.62 to −0.38; high-grade evidence) and Parkinsonism (SMD −0.41, 95% CI −0.75 to −0.08; moderate evidence).
  • Dronabinol had moderate evidence of benefit for chronic pain (SMD −0.31), appetite (SMD −0.51), and Tourette (SMD −1.01).
  • Nabiximols had moderate evidence of benefit for chronic pain (SMD −0.25), spasticity (SMD −0.36), sleep (SMD −0.24), and SUDs (SMD −0.48).
  • For safety, cannabinoids increased adverse events: e.g., dronabinol vs placebo OR 2.16, nabiximols OR 1.97, nabilone OR 3.12; however, overall retention was not significantly different (OR 1.12, P = 0.1).

## Methods

  • Systematic review and meta-analysis of randomized controlled parallel and cross-over trials of dronabinol, nabilone, cannabidiol (CBD), and nabiximols, registered at PROSPERO (CRD42021229932) and conducted per PRISMA.
  • Searched 8 databases through May 2021 with an update in October 2021; included humans of any age/sex with a medical condition and excluded non-RCT designs and smoked marijuana/other undefined cannabis products.
  • Main analysis pooled continuous outcomes as SMDs and dichotomous outcomes as ORs using random-effects models, with subgroup analyses by cannabinoid type and comparator, plus meta-regression for subtype comparisons.

## Limitations

  • The paper states that 15% of all studies (31% of all comparisons) could not be graded because they were single RCTs for ALS, Chorea Huntington, dystonia, glaucoma, ADHD, anorexia, and PTSD, so they were not included in the conclusions.
  • The paper states that missing trials—especially for CBD—often prevented direct comparison across cannabinoid types, limiting conclusions.
  • The paper states that many RCTs had small sample sizes, and that differences in sample characteristics, trial duration, dose, and route of administration contributed to heterogeneity; it also says a broader meta-regression with those covariates was not possible due to the small number of studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12916-022-02459-1

Cites

266 of 266 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA flowchart of the studies
Fig. 1 PRISMA flowchart of the studiesCC BY · PubMed Central
Fig. 2 GRADE summary graph. Percentage of studies showing high, moderate, low, very low evidence and single RCTs for each cannabinoid type (A) and outcome (B)
Fig. 2 GRADE summary graph. Percentage of studies showing high, moderate, low, very low evidence and single RCTs for each cannabinoid type (A) and outcome (B)CC BY · PubMed Central
Fig. 3 Chronic pain forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 3 Chronic pain forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 4 Spasticity forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 4 Spasticity forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 5 Appetite forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 5 Appetite forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 6 Epilepsy forest plot. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 6 Epilepsy forest plot. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 7 Parkinson’ disease forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 7 Parkinson’ disease forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 8 Sleep forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 8 Sleep forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 9 SUDs forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 9 SUDs forest plot, stratified according to cannabinoid type and comparator used. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central
Fig. 10 Tourette forest plot. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effect
Fig. 10 Tourette forest plot. The horizontal lines indicate 95% CIs. The diamond markers represent the subtotal and overall weighed standardized mean difference (SMD) mean difference and 95% CI. The vertical line shows the line of no effectCC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 1 Not valid · 10 Not checked · 83 Own results and interpretations

46 more claims

Create a free account to see all 99 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 9
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

2 of 2

Citations

Cites

Show all 266 references

Research works printed but not linked: 3

  1. Schimrigk S, Marziniak M, Neubauer C, Kugler EM, Werner G, Abramov-Sommariva D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78(5–6):320–9. · DOI · Paper page
  2. Higgins JPT Page MJ, Elbers RG, Sterne JAC. SJ. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions version 62 (updated February 2021) Cochrane, 2021
  3. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University, (developed by Evidence Prime, Inc.). 2012.

Cited by

See all 181

Metadata

Authors
Bilbao, A., & Spanagel, R.
Affiliations
Heidelberg University (DE)
Corresponding author
Bilbao, Ainhoa
Venue
BMC Medicine
Published
2022-08-19
Volume
20
Issue
1
Pages
259-259
ISSN
1741-7015 (ISSN-L)
OpenAlex
W4292508586
Cited by
181
References
266
Citations by year
2026: 33 · 2025: 49 · 2024: 63 · 2023: 30 · 2022: 6
FWCI
5.31
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • BMBF (FKZ: 01ZX1909A)
  • German Research Foundation (ID 402170461, SFB1158 (B04))
  • Zentralinstitut für Seelische Gesundheit (ZI)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Health Sciences › Medicine › Internal Medicine › General Medicine and Therapeutics
Keywords
dronabinol, nabilone, cannabidiol, nabiximols, chronic pain, spasticity, nausea and vomiting, appetite, epilepsy, Tourette syndrome, substance use disorders, glaucoma, multiple sclerosis, Huntington's disease, treatment retention, adverse events, treatment efficacy, patient-reported outcomes, quality of evidence, risk of bias
MeSH terms
Cannabinoids, Humans, Nausea, Dronabinol, Vomiting, Chronic Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. https://app.cochat.ai/papers/10.1186/s12916-022-02459-1
The paper
Bilbao, A., & Spanagel, R. (2022). Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine. https://doi.org/10.1186/s12916-022-02459-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.